SPEAKERS:
- Johanna Rossell, SVP, General Manager Rare Disease, Sumitomo Pharma America
- Karin Pihel, Senior Director, Regulatory Affairs, Sumitomo Pharma America
KEY TAKEAWAYS:
• Pursue multiple regulatory designations simultaneously for strategic optionality
• Collaborative scientific exchange with regulators outweighs submission speed for approval success
• Patient support infrastructure enables market access beyond clinical efficacy
• Rare disease business models require different internal justification metrics
• Digital and AI tools multiply efficiency for dispersed populations
The Complete Response Letter arrived with concerns that could have triggered an immediate resubmission sprint. Instead, Sumitomo Pharma America made a counterintuitive choice that would define their rare disease strategy. That strategic pause—prioritizing ongoing dialogue with the FDA to support informed review, over speed—led to approval eighteen months later. Today, the decision validates itself in sustained market performance. "We were able to bring RETHYMIC to market more than two years ago and have been successful in the market," Rossell confirmed. This deliberate approach to regulatory setbacks exemplifies how rare disease development demands fundamentally different playbooks than traditional pharma commercialization.
Building the Regulatory Foundation Through Strategic Pathway Selection
The regulatory landscape for rare diseases offers multiple acceleration mechanisms, but strategic value emerges only through early, comprehensive engagement. "Some of these designations include RMAT designation, which is specifically for regenerative medicine, orphan drug designation for rare diseases, accelerated approval, and then there are some early access pathways as well," Karin Pihel explained. These pathways create differentiated FDA engagement opportunities, but timing determines their utility. Companies that wait until late-stage development forfeit advantages that shape clinical programs from inception.
Sumitomo's experience demonstrates the power of simultaneous multi-pathway pursuit. "At Sumitomo Pharma, we had the experience that we applied for a number of these and it was very beneficial to us," Pihel noted. This portfolio approach creates optionality—different programs require varying evidence thresholds, with some accessible before clinical data generation. Strategic pathway selection becomes a development accelerator when integrated with clinical and commercial planning.
Beyond designation mechanics lies a more fundamental regulatory dimension: agency education.
"Our responsibilities include collaborative scientific exchange with regulators about unmet need, natural history, and clinical data,"
Pihel emphasized. For ultra-rare diseases, FDA reviewers may lack institutional knowledge about practice patterns, patient workflows, and real-world treatment complexity. Company-led education becomes strategic investment rather than compliance burden.
This educational imperative connects directly to commercial success through what Rossell characterizes as an integration framework. "I always call it the triangle of regulatory, clinical development, and the unmet need. Commercial development is building that input," she explained. When regulatory strategy, clinical evidence generation, and commercial planning inform each other from earliest stages, pathway advantages compound. Accelerated FDA feedback enables earlier market preparation, stakeholder education, and value proposition refinement—critical advantages when market access depends on demonstrating value to unfamiliar payer and provider audiences.
Justifying Investment Through New Business Model Metrics
Rare disease programs face dual skepticism: internal stakeholders applying traditional pharma metrics and external audiences unfamiliar with disease existence. The internal challenge requires fundamental metric transformation. "Our populations are smaller, but the value per customer is a lot higher," Rossell acknowledged. Peak sales projections and market share calculations systematically undervalue rare disease opportunities. Success requires reframing: from volume to per-patient lifetime value, from market share to market creation, from field force efficiency to patient journey coordination capability.
This business model shift demands comprehensive stakeholder education extending far beyond traditional marketing. Patient advocacy groups, scientific societies, and healthcare providers may never have encountered specific ultra-rare conditions. "These are patient families that have never heard about this disease before," Rossell noted. Education begins before diagnosis and continues through treatment and follow-up, coordinating pediatricians, centers of excellence, specialized sites, payers, and families.
The educational burden intensifies when practice patterns differ fundamentally from typical medication administration. "We were working on a product that was an ultra-rare disease, and there were so many things about the practice that were different than other types of medications," Pihel reflected. When regulators require education about basic treatment workflows, the broader healthcare ecosystem needs proportionally greater support. This reality transforms education from marketing expense to foundational infrastructure enabling all downstream commercial activity.
External stakeholders become partners when they recognize genuine commitment to unmet needs.
"The beauty of rare diseases is that even though your therapy won't solve the problems for all of the population or large amounts of patients, most likely you are solving the challenges for healthcare providers who are having the most difficulties,"
Rossell explained. Patient advocacy groups amplify awareness through networks traditional marketing cannot access. Scientific societies provide credibility that accelerates provider adoption. These partnerships deliver disproportionate value in rare disease contexts where target audiences are small, dispersed, and difficult to identify through conventional channels.
Operationalizing Access Through Comprehensive Patient Support Infrastructure
Patient support programs in rare disease function as fundamental market access infrastructure rather than ancillary services. The operational timeline extends across months, beginning long before treatment administration. "The foundation of our success is identifying the insights that we need to generate value," Rossell stated. Families receive diagnoses for conditions they have never heard of, then navigate payer approval processes, site preparation, treatment coordination, and long-term follow-up.
This coordination challenge encompasses multiple stakeholder groups requiring tailored education and support. "We have a series of stakeholders that we need to keep educated on how the patient needs to be treated before they go to the institution," Rossell emphasized. Pediatricians need disease awareness and referral protocols. Centers of excellence require treatment logistics and patient selection guidance. Specialized administration sites need preparation for complex procedures. Payers demand evidence for coverage decisions. Families need comprehensive journey support from diagnosis through post-treatment care.
The support infrastructure fills gaps that even specialized centers cannot fund. "The centers of excellence don't have the money to support this level of comprehensive care. So we fill that gap and provide representation and support along the entire journey," Rossell explained. This makes it a company responsibility directly impacting treatment completion rates and revenue realization.
Regulatory planning must anticipate these post-approval operational realities during development. "Regulatory planning also needs to anticipate post-approval realities," Pihel stressed. Site readiness, product delivery logistics, healthcare system infrastructure, and training requirements all require advance planning to ensure approval translates to actual patient access. "Health systems are ready, so they will need the infrastructure, training, and resources so that they can safely treat patients with these very complex therapies," she added.
For one-time treatments, additional complexity emerges in transitioning patients back to home-state care after administration at specialized centers. "Most of the time, we help bring them back to their home states where they need to continue their care, because our treatment is not ongoing—it's a one-time treatment," Rossell noted. Comprehensive support programs must coordinate this handoff, ensuring local providers understand post-treatment monitoring and long-term care requirements. This infrastructure protects revenue by maximizing treatment completion, generates real-world evidence supporting future indications, and strengthens relationships with key treatment centers.
Leveraging Digital Transformation for Rare Disease Efficiency
The integrated regulatory-commercial approach provides foundation for leveraging emerging technological opportunities that are reshaping rare disease economics. Digital tools and artificial intelligence transform traditional constraints into advantages. "I feel like we've been doing business internationally for a long time, but considering that we invest a lot of money in research with these companies nowadays, the most valuable tools for us are AI and digital technology," Rossell observed. Active patient communities on social media enable targeted identification without proportional infrastructure investment.
Regulatory frameworks are evolving to embrace these technological shifts.
"We're seeing more openness to flexible and adaptable regulatory frameworks, the introduction of real-world evidence into filings, and also new pilot programs that are trying to keep up with the faster pace of scientific advancement,"
Pihel observed. Real-world evidence serves dual commercial purposes: supporting novel trial designs for small populations and building post-launch payer and provider confidence.
The integration framework that connects regulatory strategy, clinical development, and commercial planning becomes even more powerful when amplified by digital tools. "These patient communities are very active on the internet and social media, so we can reach them faster and less costly," Rossell explained. This triangle now operates at digital speed, with AI enabling rapid hypothesis testing, patient identification, and stakeholder coordination that previously required years of relationship building.
Academic and industry partnerships strengthen this foundation. "If you can work with academia and collaborate on generating data, this type of data can strengthen the credibility of the product and help with approval, but also with adoption and confidence in the therapy post-launch," Pihel noted. These collaborations generate evidence that serves both regulatory and commercial objectives simultaneously.
Principles for Future-Ready Rare Disease Success
Strategic advantage accrues to organizations mastering this integrated approach: regulatory agility through early pathway engagement and comprehensive agency education, digital efficiency in patient identification and stakeholder coordination, comprehensive support infrastructure enabling treatment completion, and evidence generation partnerships supporting both approval and adoption. "Definitely engage with regulators early and often. Never underestimate the power of your collaborations, both internally within your organization and externally," Pihel advised.
The transformation of a Complete Response Letter into sustained market success illustrates these principles in practice. Strategic patience in regulatory education, comprehensive stakeholder coordination, robust patient support infrastructure, and efficient resource deployment through targeted partnerships created competitive advantages that traditional pharma playbooks systematically miss. "If you have the scientific data available to demonstrate that your therapy is working and you are keeping the patient needs at the forefront, regulatory success will follow," Pihel concluded.
Companies that master this integrated approach unlock high-value opportunities in populations that conventional metrics undervalue. "By building that value proposition—if your drug has enough value to be in the treatment algorithm and to change the way these patients are being treated—and you're ready to demonstrate that value, your stakeholders are going to partner with you," Rossell emphasized. The rare disease space rewards organizations that move quickly, educate comprehensively, and operate efficiently—all enabled by technologies reducing traditional barriers while maintaining patient-centered focus throughout the development and commercialization journey.
To get you highlights of Pharma Customer Engagement USA faster, we are using generative AI technology to summarise the transcripts of the sessions. If you have any feedback about the summary, please contact lucy.fisher@thomsonreuters.com.
Discover more on this topic at Pharma USA 2026 (March 17-18, Philadelphia) - North America's largest cross-functional pharma gathering. Visit the website here.
